asthma
chronic
obstruct
pulmonari
diseas
copd
common
diseas
result
signifi
cant
morbid
mortal
although
share
clinic
featur
although
may
coexist
individu
distinct
diseas
syndrom
diff
erent
pathogenet
mechan
case
much
morbid
mortal
associ
exacerb
diseas
respons
varieti
trigger
factor
common
featur
asthma
copd
import
role
infect
trigger
exacerb
infect
also
implic
etiolog
two
diseas
th
chapter
review
epidemiolog
evid
implic
infecti
pathogen
trigger
discuss
mechan
interact
hostpathogen
respons
preexist
airway
patholog
result
exacerb
asthma
aff
ect
children
unit
kingdom
multifacet
syndrom
involv
atopi
bronchial
hyperreact
ige
nonigemedi
acut
chronic
immun
respons
th
e
asthmat
airway
character
infi
ltrate
eosinophil
tlymphocyt
express
type
cytokin
trigger
factor
associ
acut
exacerb
asthma
includ
exposur
environment
allergen
especi
anim
mold
pollen
mite
cold
exercis
drug
th
e
link
respiratori
infect
asthma
exacerb
well
establish
although
incomplet
understood
associ
attribut
bacteri
allergi
clear
major
exacerb
due
viral
rather
bacteri
infect
viral
respiratori
tract
infect
major
caus
wheez
infant
adult
patient
asthma
th
eir
role
may
underestim
earli
epidemiolog
studi
diffi
culti
isol
identifi
cation
th
e
introduct
pcr
studi
implic
viral
infect
major
asthma
exacerb
indirect
evid
popul
studi
establish
signifi
cant
correl
season
variat
wheez
episod
young
children
peak
viru
identifi
cation
season
pattern
identifi
cation
respiratori
virus
associ
peak
hospit
admiss
children
adult
asthma
indic
role
infect
sever
asthma
attack
direct
evid
implic
viral
infect
asthma
exacerb
provid
studi
show
increas
rate
viru
detect
individu
suff
ere
asthma
attack
virus
detect
asthma
exacerb
children
adult
th
e
highest
rate
identifi
cation
studi
subject
follow
prospect
allow
collect
clinic
specimen
earli
cours
ill
pcrbase
method
diagnosi
use
instead
addit
serolog
cultur
methodolog
use
allow
detect
rhinovirus
th
e
rate
detect
virus
exacerb
individu
asymptomat
order
contrast
studi
transtrach
aspir
adult
asthmat
exacerb
yield
spars
bacteri
cultur
correl
clinic
ill
diff
erenc
normal
subject
almost
studi
asthmat
predomin
virus
rhinovirus
rv
infl
uenza
rsv
parainfl
uenza
virus
rv
alon
detect
around
virusinduc
asthma
attack
adenovirus
enterovirus
metapneumovirus
bocavirus
coronavirus
also
detect
less
frequent
infl
uenza
found
annual
epidem
th
e
eff
ect
respiratori
viru
infect
nasal
mucosa
upper
respiratori
tract
extens
investig
th
e
eff
ect
virus
lower
respiratori
tract
studi
detail
knowledg
pathogenet
mechan
involv
asthma
exacerb
remain
limit
experiment
respiratori
viru
infect
human
volunt
limit
mild
diseas
concern
safeti
studi
therefor
focus
experiment
innocul
rhinoviru
allerg
rhinit
mild
asthmat
individu
normal
control
subject
studi
provid
use
model
natur
viru
infect
asthma
er
advantag
patient
select
monitor
control
condit
infect
administr
activ
placebo
medic
abil
sampl
lower
airway
time
onset
infect
accur
defi
ned
studi
rvinduc
eff
ect
includ
asthma
symptomatolog
lung
function
airway
pathologyimmunolog
recent
epidemiolog
evid
confi
rm
synergist
interact
viru
infect
allergen
exposur
precipit
hospit
admiss
asthma
trigger
factor
may
interact
infect
includ
air
pollut
studi
asthmat
children
demonstr
increas
risk
develop
asthmat
episod
within
day
upper
respiratori
tract
infect
nitrogen
dioxid
level
greater
gm
studi
experiment
viru
infect
allerg
subject
perform
outsid
relev
season
allergen
exposur
one
attempt
provid
model
combin
allergen
exposur
viru
infect
util
rv
infect
subject
allerg
rhiniti
individu
receiv
three
high
dose
allergen
challeng
week
prior
innocul
tri
mimic
combin
allergen
exposur
viru
infect
interestingli
prior
allergen
challeng
model
somewhat
unexpectedli
appear
protect
rv
cold
delay
nasal
leukocytosi
increas
gener
proinfl
ammatori
cytokin
delay
less
sever
clinic
cours
th
ere
invers
correl
nasal
lavag
eosinophilia
sever
cold
symptom
th
e
explan
propos
author
studi
limit
high
dose
allergen
challeng
may
reproduc
eff
ect
chronic
low
dose
allergen
exposur
may
stimul
product
antiinfl
ammatori
mediat
antivir
cytokin
work
de
kluijver
et
al
eff
ect
period
low
dose
allergen
exposur
housedust
mite
sensit
andor
experiment
infect
studi
synergist
addit
eff
ect
observ
regard
lung
function
paramet
develop
model
experiment
combin
allergen
exposur
viru
infect
clearli
requir
recent
adopt
approach
infect
asthmat
volunt
rv
send
home
continu
normal
allergen
exposur
natur
environ
investig
physiolog
virolog
immunopatholog
respons
experiment
rhinoviru
infect
blood
induc
sputum
bronchial
lavag
atop
mild
asthmat
nonatop
normal
volunt
rhinoviru
infect
induc
significantli
greater
lower
respiratori
symptom
lung
function
impair
increas
bronchial
hyperreact
eosinophil
lower
airway
infl
ammat
asthmat
compar
normal
subject
also
saw
trend
increas
neutrophil
lymphocyt
lower
airway
asthmat
coincid
reduct
blood
lymphocyt
suggest
traffi
cking
airway
asthmat
normal
subject
viru
load
signifi
cantli
relat
lower
respiratori
symptom
bronchial
hyperreact
reduct
blood
total
lymphocyt
lung
function
impair
signifi
cantli
relat
neutrophil
eosinophil
lower
airway
infl
ammat
th
studi
demonstr
increas
rhinovirusinduc
clinic
ill
sever
asthmat
compar
normal
subject
provid
evid
strong
relationship
viru
load
lower
airway
virusinduc
infl
ammat
asthma
exacerb
sever
suggest
approach
could
provid
good
model
examin
asthma
exacerb
pathogenesi
well
treatment
intervent
wherea
respiratori
virus
infl
uenza
parainfl
uenza
rsv
adenoviru
well
recogn
caus
lower
airway
syndrom
pneumonia
bronchiol
capabl
replic
lower
airway
recent
uncertainti
whether
rv
infect
occur
lower
airway
sole
upper
respiratori
tract
although
possibl
nasopharyng
contamin
rule
rv
detect
lower
airway
clinic
specimen
sputum
tracheal
brush
bal
rtpcr
cultur
rv
cultur
cell
line
bronchial
epitheli
cell
origin
replic
demonstr
primari
cultur
bronchial
epitheli
cell
th
e
prefer
rv
cultur
rather
use
argument
lower
airway
infect
evid
replic
occur
lower
airway
temperatur
final
use
situ
hybrid
conclus
demonstr
rv
replic
bronchial
biopsi
subject
follow
experiment
infect
recent
immunochemistri
data
suggest
prefer
basal
cell
th
ese
data
confi
rm
rv
infect
lower
airway
occur
directli
implic
lower
airway
infect
pathogenesi
asthma
exacerb
investig
pathogenesi
rhinoviru
infect
rhinovirusinduc
asthma
exacerb
sever
hamper
year
sinc
discoveri
believ
rhinovirus
infect
human
chimpanze
howev
mous
model
rhinoviru
infect
recent
success
develop
fi
rst
time
new
method
purifi
cation
concentr
rhinovirus
use
show
minor
group
rhinovirus
use
ldl
receptor
mode
entri
cell
wildtyp
balbc
mice
success
infect
diseaserel
outcom
observ
human
reproduc
uniqu
new
model
th
ese
outcom
includ
induct
innat
acquir
immun
respons
induct
mucin
synthesi
secret
induct
acut
neutrophil
prolong
lymphocyt
airway
infl
ammat
induct
chemokin
respons
chemoattract
neutrophil
lymphocyt
dendrit
cell
well
rang
proinfl
ammatori
cytokin
mice
transgen
chimera
receptor
major
group
rhinovirus
rhinovirusbind
domain
human
remaind
molecul
mous
develop
th
transgen
mous
abl
infect
major
group
strain
thu
gener
mous
model
capabl
infect
rhinoviru
serotyp
final
establish
mous
model
allerg
airway
infl
ammat
use
demonstr
rhinoviru
infect
model
result
rhinovirusinduc
exacerb
allerg
airway
infl
ammat
th
e
asthmarel
outcom
exacerb
infect
model
includ
exacerb
airway
hyperrespons
exacerb
mucin
synthesi
secret
exacerb
neutrophil
eosinophil
lymphocyt
airway
infl
ammat
augment
induct
th
th
cytokin
th
e
develop
novel
mous
model
rhinovirusinduc
asthma
exacerb
allow
mechan
diseas
investig
vivo
true
causat
establish
vivo
subject
asthma
andor
allerg
rhiniti
exhibit
increas
pathophysiolog
eff
ect
result
rv
infect
compar
nonatop
nonasthmat
control
detail
monitor
possibl
detect
reduct
peak
fl
ow
home
record
fev
atop
asthmat
patient
acut
phase
experiment
infect
th
ere
enhanc
sensit
histamin
allergen
challeng
innocul
nonasthmat
atop
rhinit
subject
increas
asthma
symptom
coincid
increas
maxim
bronchoconstrict
respons
methacholin
day
infect
th
ere
also
signifi
cant
increas
sensit
histamin
asthmat
subject
infect
pronounc
sever
cold
symptom
recent
studi
confi
rmed
reduct
lung
function
increas
symptom
airway
hyperrespons
observ
asthmat
normal
subject
current
concept
typic
antivir
immun
respons
review
detail
elsewher
result
research
human
volunt
patient
also
experiment
anim
especi
inbr
mice
result
anim
studi
may
directli
applic
outbre
human
popul
ethic
consider
often
limit
direct
investig
human
immun
system
immun
respons
combin
nonspecifi
c
innat
specifi
c
adapt
immun
nonspecifi
c
innat
element
includ
phagocyt
neutrophil
macrophag
engulf
destroy
virus
natur
killer
nk
cell
recogn
destroy
virusinfect
cell
basi
reduc
hla
class
express
cell
includ
nk
cell
neutrophil
macrophag
mast
cell
basophil
epitheli
cell
releas
cytokin
interferon
immunoregulatori
antivir
action
compon
bodi
fl
uid
complement
defensin
surfact
protein
capabl
neutral
virus
independ
combin
antibodi
virus
may
also
caus
complementmedi
damag
complement
compon
bind
epitheli
cell
vitro
vivo
rsv
infect
increas
human
volunt
infect
infl
uenza
viru
th
ere
littl
inform
role
complement
immun
rv
recent
data
suggest
rv
proteas
cleav
complement
factor
may
interfer
destruct
virusinfect
cell
virus
exampl
infl
uenza
complement
system
form
import
link
innat
specifi
c
immun
system
mice
defi
cient
third
compon
complement
highli
suscept
primari
infl
uenza
show
reduc
prime
thelper
cell
cytotox
tcell
lung
drain
lymph
node
sever
impair
recruit
lung
virusspecifi
c
eff
ector
tcell
produc
activ
complement
cascad
may
necessari
function
innat
antivir
protein
serum
mannosebind
protein
defensin
th
e
defensin
small
cation
antimicrobi
peptid
capac
kill
bacteria
fungi
envelop
virus
disrupt
microbi
membran
vivo
probabl
import
phagocyt
vacuol
surfac
skin
mucos
epithelia
addit
direct
antibiot
role
defensin
increasingli
found
immunomodulatori
action
play
role
cell
recruit
activ
certain
chemokin
receptor
exampl
dendrit
cell
dc
specifi
c
immun
involv
product
antibodi
blymphocyt
activ
cytotox
tcell
follow
process
present
viral
antigen
addit
cell
immun
system
import
probabl
dendrit
cell
immunolog
memori
modifi
es
overal
respons
reinfect
previous
encount
viru
alter
time
magnitud
contribut
due
diff
erent
compon
primari
infect
virus
replic
respiratori
tract
reach
peak
level
around
day
time
type
interferon
fi
rst
detect
peak
around
day
fall
becom
undetect
activ
replic
ceas
interferon
activ
nk
cell
fi
rst
detect
around
day
peak
around
day
addit
destruct
viral
infect
cell
nk
cell
releas
cytokin
includ
activ
addit
infl
ammatori
cell
airway
includ
macrophag
nonspecifi
c
immun
mechan
essenti
earli
defens
viru
fi
rst
day
addit
innat
immun
system
play
role
stimul
specifi
c
immun
may
infl
uenc
natur
specifi
c
respons
exampl
whether
character
type
type
cytokin
meanwhil
viral
antigen
process
local
region
lymph
node
dendrit
cell
present
tcell
tcell
detect
around
day
gener
declin
infect
resolv
becom
undetect
day
howev
memori
respons
may
persist
life
tcell
recruit
depend
product
chemokin
alter
express
adhes
molecul
endothelium
infl
ame
tissu
time
also
requir
gener
bcell
respons
mucos
iga
may
detect
around
day
serum
igm
day
igg
day
increas
amount
avid
next
week
iga
fall
normal
low
undetect
level
month
serum
igg
may
remain
detect
life
specifi
c
immun
mechan
tcell
immunoglobulin
respons
erad
infecti
viru
usual
day
infect
secondari
infect
viru
result
rapid
mobil
band
tcell
specifi
c
immun
earlier
tcell
peak
coincid
nk
cell
peak
around
day
reinfect
serotyp
rapid
increas
level
preexist
neutral
antibodi
may
limit
viral
replic
extent
infect
clinic
silent
result
fewer
infect
cell
rel
less
activ
nonspecifi
c
immun
may
diffi
cult
detect
tcell
respons
follow
experiment
infect
seroneg
subject
serumspecifi
c
antibodi
detect
week
reach
maximum
week
persist
least
year
may
remain
elev
mani
year
infect
local
specifi
c
antibodi
level
may
lost
rapidli
high
level
serum
neutral
antibodi
specifi
c
iga
protect
reinfect
rhinoviru
serotyp
howev
sinc
appear
rel
late
recoveri
ill
seroneg
host
usual
occur
day
must
due
compon
immun
respons
seroposit
subject
preexist
serum
neutral
antibodi
rvhank
modifi
experiment
infect
human
subject
local
iga
igg
pass
vasculatur
pulmonari
interstitium
contribut
viral
clearanc
howev
rv
serotyp
mean
repeat
infect
rv
individu
lack
appropri
antibodi
common
tcell
respons
rv
demonstr
mhc
class
restrict
crossreact
serotyp
due
specif
conserv
epitop
within
capsid
protein
vp
c
tcell
clone
human
peripher
blood
demonstr
recognit
serotyp
specifi
c
share
viral
epitop
vigor
prolifer
product
pbmc
respons
seroneg
subject
associ
reduc
viral
shed
inocul
thu
tcell
respons
also
appear
protect
th
e
interact
respiratori
viru
infect
chronic
asthmat
airway
infl
ammat
result
respiratori
symptom
sever
suff
ere
nonasthmat
individu
casecontrol
studi
demonstr
clear
synergist
interact
viru
infect
allergen
exposur
increas
risk
exacerb
th
e
detail
immunolog
mechan
underli
interact
current
investig
recent
data
suggest
defi
cient
product
type
type
ii
type
iii
ifn
well
th
cytokin
antiinfl
ammatori
cytokin
like
increas
virusinduc
lower
airway
infl
ammat
th
ese
defi
cienci
also
accompani
augment
product
th
cytokin
suggest
perhap
allergeninduc
infl
ammat
also
increas
pathogenesi
virusinduc
asthma
exacerb
bronchial
infl
ammat
like
therefor
central
event
virusinduc
asthma
exacerb
th
e
process
involv
includ
interact
cascad
complement
coagul
fi
brinolyt
kinin
system
plasma
well
cellderiv
cytokin
chemokin
arachidon
acid
metabolit
understand
interact
virus
cascad
asthma
incomplet
like
diff
erent
virus
interact
system
diff
erent
extent
howev
reason
believ
case
initi
trigger
infl
ammatori
reaction
epitheli
cellviru
interact
th
e
airway
epithelium
import
compon
antivir
defens
addit
function
physic
barrier
entri
virus
respons
epitheli
cell
ec
follow
viral
infect
whether
result
destruct
cell
contribut
innat
adapt
antivir
immun
respons
inform
regard
eff
ect
rv
ec
come
vivo
studi
vitro
model
use
either
cultur
primari
airway
ec
cell
line
epitheli
cell
origin
ec
contribut
immun
respons
follow
viru
infect
product
cytokin
chemokin
fig
th
ey
may
also
act
antigen
present
cell
particularli
secondari
respiratori
viral
infect
epitheli
cell
express
mhc
class
costimulatori
molecul
express
upregul
vitro
fig
th
e
extent
epitheli
cell
destruct
observ
airway
vari
accord
viru
type
infl
uenza
typic
caus
extens
necrosi
wherea
rv
caus
littl
patchi
damag
destruct
epitheli
cell
result
increas
epitheli
permeabl
increas
penetr
irrit
allergen
exposur
extens
network
aff
erent
nerv
fi
ber
eff
ect
may
contribut
increas
bronchial
hyperrespons
vivo
rv
caus
shed
infect
ciliat
ec
extent
viral
infect
epithelium
may
incomplet
even
nose
vitro
studi
expos
monolay
cultur
nasal
epitheli
cell
respiratori
virus
tcid
ml
demonstr
detect
cpe
carboxypeptidas
e
rv
coronaviru
contrast
extens
destruct
infl
uenza
adenoviru
ex
vivo
infect
cell
upper
lower
respiratori
tract
suggest
less
cell
epithelium
infect
rv
howev
extent
virusinduc
epitheli
damag
may
consider
greater
asthmat
normal
subject
asthmat
epithelium
shown
much
suscept
vitro
vivo
studi
degre
epitheli
damag
would
technic
challeng
could
gener
interest
fi
nding
virus
enter
replic
within
airway
ec
entri
depend
interact
host
cell
surfac
protein
function
receptor
case
major
group
rv
infect
block
antibodi
solubl
th
ere
rel
limit
express
airway
epithelium
prior
rv
infect
may
explain
patchi
natur
infect
th
e
upregul
asthmat
airway
one
possibl
explan
increas
sever
rv
infect
asthma
rv
upregul
express
receptor
vitro
vivo
follow
experiment
infect
rv
express
upregul
nasal
epithelium
within
h
declin
day
rv
similar
eff
ect
ec
lower
airway
rv
shown
upregul
primari
bronchial
ec
vitro
upregul
bronchial
biopsi
follow
experiment
infect
asthmat
subject
th
ere
two
form
membran
bound
favor
viral
infect
act
viru
receptor
solubl
bind
viru
outsid
cell
therebi
inhibit
viru
infect
rv
infect
ec
report
alter
balanc
favor
infect
induc
mrna
whilst
suppress
th
e
ldl
receptor
receptor
minor
group
rv
infect
primari
human
tracheal
ec
phtec
block
antibodi
ldl
receptor
also
report
upregul
ldlr
express
express
human
nasal
ec
upregul
vitro
exposur
number
infl
ammatori
cytokin
mediat
includ
eosinophilderiv
protein
mbp
ecp
particular
may
import
rvinduc
induct
antibodi
decreas
viral
replic
express
phtec
respiratori
epitheli
cell
line
behav
way
primari
ec
exampl
cell
express
lower
level
constitut
show
upregul
ecp
mbp
th
e
eff
ect
complex
whilst
upregul
uninfect
cell
cytokin
inhibit
upregul
cell
presenc
result
reduc
viral
titer
preexist
elev
express
asthmat
airway
may
contribut
increas
symptom
sever
rv
infect
type
cytokin
upregul
cell
allergen
challeng
result
upregul
conjunctiv
nasal
ec
atop
nasal
brush
ec
atop
basal
level
increas
rel
nonatop
elev
relev
allergen
season
nasal
ec
atop
show
upregul
vitro
cultur
allergen
th
e
highest
basal
found
nasal
polyp
ec
increas
infect
viral
titer
infect
signifi
cantli
higher
polyp
ec
nonatop
atop
nonpolyp
ec
modifi
cation
ec
express
therefor
possibl
therapeut
benefi
vitro
rv
increas
express
primari
bronchial
ec
pbec
cultur
cell
via
mechan
involv
b
one
action
corticosteroid
inhibit
b
cell
pbec
pretreat
three
corticosteroid
hydrocortison
dexamethason
mometason
furoat
inhibit
increas
surfac
express
mrna
promot
activ
without
alter
viru
infect
replic
dexamethason
suppress
phtec
inhibit
rv
infect
dexamethason
inhibit
infect
phtec
minor
group
disappointingli
studi
inhal
corticosteroid
asthmat
prior
experiment
rv
infect
fail
show
reduc
virusinduc
express
bronchial
biopsi
possibl
longer
cours
andor
higher
dose
inhal
steroid
administr
oral
steroid
might
demonstr
signifi
cant
eff
ect
drug
aff
ect
ec
includ
reduc
agent
h
receptor
antagonist
desloratidin
loratidin
inhibit
rvinduc
upregul
hpbec
cell
erythromycin
inhibit
infect
phtec
major
group
minor
group
eff
ect
includ
reduct
blockag
rv
rna
entri
endosom
small
reduct
ldl
receptor
express
ec
activ
recruit
varieti
cell
type
lymphocyt
eosinophil
neutrophil
product
chemokin
cytokin
fig
cell
import
compon
antivir
respons
may
also
contribut
airway
infl
ammat
dysfunct
asthma
interferon
ifn
play
import
role
innat
resist
virus
act
virusinfect
cell
surround
cell
produc
antivir
state
character
express
antivir
activ
ifnstimul
gene
isg
th
ere
three
main
type
ifn
type
type
recent
discov
type
ec
produc
type
type
ifn
th
ere
gene
gene
synthesi
involv
b
atfjun
interferon
regulatori
factor
irf
current
identifi
ed
activ
occur
respons
virusspecifi
c
signal
includ
dsrna
product
replic
ssrna
virus
rv
rsv
infl
uenza
express
earli
action
activ
ifn
intracellular
signal
pathway
requir
induct
requir
transcript
full
rang
ifn
dna
microarray
analysi
shown
follow
bind
receptor
target
cell
ifn
trigger
complex
signal
pathway
mainli
jakstat
result
transcript
hundr
isg
sever
isg
well
studi
th
ese
includ
dsrnaactiv
serinethreonin
protein
kinas
pkr
reduc
cellular
mrna
translat
transcript
event
two
enzym
involv
mrna
degrad
oligoadenyl
synthetas
oa
rnase
l
myxoviru
resist
mx
protein
rnaspecifi
c
adenosin
deaminas
adar
involv
rna
edit
th
ese
isg
inhibit
viru
replic
number
level
surprisingli
virus
evolv
mechan
resist
action
ifn
exampl
block
pkr
infl
uenza
protein
ifn
also
upregul
cellular
express
mhc
class
ii
molecul
therefor
increas
antigen
present
tcell
enhanc
cellular
immun
respons
one
recent
studi
examin
type
interferon
product
primari
bronchial
epitheli
cell
normal
asthmat
subject
infect
ex
vivo
rv
asthmat
ec
follow
infect
releas
higher
titer
viru
cultur
supernat
exhibit
impair
apoptosi
greater
degre
necrot
cell
death
favor
releas
viru
die
cell
th
accompani
lower
concentr
infect
addit
asthmat
ec
inhibit
viru
replic
level
observ
ec
normal
subject
th
studi
suggest
product
defi
cient
asthmat
ec
replacementaugment
boost
innat
immun
respons
could
novel
approach
treatment
virusinduc
asthma
exacerb
new
famili
interferon
call
type
iii
character
three
element
also
term
recent
describ
th
e
three
highli
homolog
protein
demonstr
limit
homolog
type
ifn
human
bind
uniqu
heterodimer
receptor
r
compos
also
design
also
design
share
class
ii
cytokinereceptor
ligand
includ
viral
infect
induc
upregul
mrna
epitheli
cell
peripher
blood
mononuclear
cell
pbmc
dendrit
cell
exhibit
similar
biolog
properti
type
ifn
induc
jakstat
pathway
lead
upregul
sever
antivir
protein
enzym
includ
oa
mxa
antivir
activ
vitro
also
exhibit
antvir
activ
vivo
model
vaccinia
virusinfect
mice
base
current
knowledg
thu
appear
ligandreceptor
system
independ
induc
antivir
state
engag
similar
particip
antivir
respons
though
signal
pathway
involv
product
current
larg
unknown
recent
data
suggest
may
involv
antivir
respons
rv
vitro
rv
infect
bronchial
epitheli
cell
line
led
product
cytokin
demonstr
dosedepend
antivir
eff
ect
rv
moreov
product
occur
vitro
infect
primari
bronchial
epitheli
cell
macrophag
bal
cell
healthi
volunt
recent
investig
product
respons
rv
primari
bronchial
ec
bal
cell
macrophag
normal
asthmat
subject
product
defici
ec
bal
cell
asthmat
subject
vitro
rv
infect
induct
rv
infect
ec
strongli
invers
relat
rv
replic
determin
whether
product
import
determin
respons
rv
infect
vivo
volunt
experiment
infect
sever
symptom
reduct
lung
function
monitor
viru
load
determin
bal
vitro
product
rv
infect
bal
cell
strongli
invers
correl
common
cold
symptom
vivo
viru
load
strongli
posit
correl
sever
fall
lung
function
asthmat
normal
volunt
experiment
infect
asthmat
patient
vitro
product
bal
cell
signifi
cantli
lower
normal
subject
exhibit
increas
common
cold
symptom
reduct
lung
function
viru
load
vivo
infect
mark
contrast
normal
subject
robust
respons
less
sever
cold
symptom
lower
viru
load
signifi
cant
chang
lung
function
th
ese
result
document
import
host
defens
rv
infect
vitro
vivo
indic
defi
cient
product
like
import
pathogenesi
virusinduc
asthma
exacerb
viral
infect
respiratori
tract
result
signific
chang
pattern
cytokin
express
number
cell
type
cell
immun
system
may
increas
number
activ
statu
cell
often
consid
structur
fact
contribut
signifi
cantli
immun
respons
ec
effi
cient
orchestr
immun
respons
cytokin
essenti
erad
viru
modifi
cation
cytokin
express
airway
may
contribut
increas
sever
viru
infect
asthma
vitro
studi
bronchial
ec
line
macrophag
demonstr
product
wide
rang
proinfl
ammatori
cytokin
granulocytemacrophag
coloni
stimul
factor
gmcsf
chemokin
rant
macrophag
infl
ammatori
protein
mip
respons
rv
rsv
vivo
cytokin
found
nasal
lavag
associ
rv
infect
th
e
specifi
c
role
individu
cytokin
human
lower
airway
viral
infect
well
understood
increas
inform
becom
avail
cytokin
chemokin
activ
recruit
varieti
cell
includ
lymphocyt
eosinophil
neutrophil
share
proinfl
ammatori
properti
induct
acut
phase
respons
activ
tand
blymphocyt
enhanc
adhes
infl
ammatori
cell
endothelium
facilit
chemotaxi
potent
antivir
cytokin
vitro
increas
suscept
cultur
epitheli
cell
infect
upregul
shown
stimul
igamedi
immun
respons
may
also
import
virusinduc
asthma
appear
caus
bronchoconstrict
direct
eff
ect
bronchial
smooth
muscl
product
cytokin
human
stromal
cell
vitro
increas
rsv
parainfl
uenza
type
cytomegaloviru
cmv
herp
simplex
viru
hsv
adenoviru
vivo
elev
nasal
aspir
children
cold
level
correl
presenc
wheez
similarli
chemokin
increas
nasal
secret
natur
viral
exacerb
asthma
studi
knockout
mice
suggest
mediat
pneumon
due
infl
uenza
th
e
chemokin
recruit
activ
neutrophil
rant
lymphocyt
viral
upregul
cytokin
chemokin
may
mediat
certain
key
transcript
factor
increas
product
cultur
epitheli
cell
due
rv
depend
b
upstream
protein
kinas
r
pkr
mediat
rvinduc
rant
rhinoviru
induct
shown
requir
ikappab
kinasebeta
ikk
transcript
factor
well
b
similar
observ
made
regard
induct
rsv
thu
potenti
role
inhibit
b
context
gener
consider
interest
addit
induct
rv
infect
result
substanti
increas
vivo
vitro
th
rel
late
eff
ect
occur
h
infect
may
contribut
symptom
resolut
multitud
infl
ammatori
mediat
gener
act
epitheli
surfac
bradykinin
anineamino
acid
peptid
gener
plasma
precursor
part
infl
ammatori
process
shown
present
nasal
secret
rvinfect
individu
bradykinin
given
intranas
abl
reproduc
symptom
common
cold
sore
throat
rhiniti
although
presenc
kinin
lung
virusinfect
individu
report
present
upper
lower
airway
allerg
reaction
nitric
oxid
produc
divers
sourc
includ
epitheli
endotheli
smooth
muscl
cell
human
airway
appear
import
relax
human
airway
smooth
muscl
nitric
oxid
may
import
rang
respiratori
diseas
includ
asthma
viru
infect
produc
constitut
enzym
nitric
oxid
synthas
no
induc
calciumindepend
express
airway
ec
macrophag
asthma
increas
express
elev
level
exhal
fall
corticosteroid
therapi
level
exhal
correl
sputum
eosinophilia
methacholin
respons
contrast
stabl
copd
exhal
level
diff
erent
normal
subject
although
may
increas
exacerb
fact
vitro
cigarett
smoke
reduc
cytokineinduc
mrna
express
murin
cell
line
cell
phbec
th
e
rel
import
benefi
cial
antimicrobi
activ
versu
potenti
disadvantag
suppress
may
depend
specifi
c
pathogen
knockout
mice
show
increas
suscept
infect
perhap
releas
may
import
nk
cellmedi
target
cell
kill
howev
may
also
possess
antivir
activ
vitro
rv
induc
no
express
hpbec
th
ere
increas
express
mrna
cultur
hpbec
infect
inhibit
rvinduc
product
gmcsf
viral
replic
human
respiratori
epitheli
cell
line
rsv
also
induc
increas
nitrit
level
supernat
cell
hpbec
cultur
bal
fl
uid
rsvinfect
balbc
mice
eff
ect
oppos
dexamethason
unaff
ect
replic
rsv
cell
inhibit
follow
transfect
retrovir
construct
contain
no
inhibit
abolish
no
inhibitor
ngmethyl
arginin
replic
infl
uenza
b
mabin
darbi
kidney
cell
sever
impair
donor
nitroson
acetylpenicillamin
overal
evid
vivo
increas
lower
airway
product
may
benefi
virusinduc
asthma
exacerb
work
guinea
pig
model
suggest
one
mechan
increas
airway
hyperrespons
respiratori
viru
infect
inhibit
no
enzym
loss
norel
relax
airway
smooth
muscl
studi
human
asthmat
would
also
suggest
protect
role
virusinduc
exacerb
follow
experiment
infect
patient
greatest
increas
exhal
smaller
increas
histamin
airway
respons
experiment
anim
parainfl
uenza
virusinduc
hyperreact
correl
defi
cienci
constitut
product
increas
level
exhal
found
nonasthmat
volunt
follow
natur
cold
well
asthmat
patient
experiment
rv
infect
latter
studi
invers
associ
increas
worsen
airway
hyperrespons
demonstr
argu
favor
protect
role
substanc
th
support
observ
reduc
cytokin
product
viral
replic
vitro
model
rv
infect
interestingli
studi
viral
upper
respiratori
tract
infect
fail
demonstr
increas
nasal
experiment
rsv
rv
infl
uenza
infect
normal
subject
experiment
infl
uenza
infect
increas
oral
day
postinfect
eff
ect
nasal
th
rais
possibl
respiratori
viru
infect
induct
select
lower
respiratori
tract
th
e
respons
airway
ec
viru
infect
consequ
interact
viru
intracellular
signal
pathway
host
cell
knowledg
mechan
involv
rhinovirus
current
limit
activ
signal
pathway
may
depend
cell
surfac
receptor
ldlr
bind
may
occur
viral
replic
within
cell
th
e
need
replic
viru
demonstr
inhibit
rv
induct
ec
cytokin
uv
inactiv
one
product
replic
common
ssrna
virus
rv
also
rsv
infl
uenza
dsrna
shown
activ
compon
signal
pathway
includ
dsrnadepend
protein
kinas
pkr
ikk
b
mitogenactiv
protein
kinas
result
induct
rant
activ
ec
dsrna
may
direct
indirect
interferon
system
discuss
also
report
dsrna
viru
infect
activ
ec
bind
studi
util
isol
rabbit
tissu
human
cultur
airway
smooth
muscl
cell
suggest
exposur
viru
may
direct
eff
ect
smooth
muscl
cell
result
increas
contractil
acetylcholin
impair
relax
isoproterenol
th
eff
ect
depend
appear
involv
autocrin
signal
mechan
includ
upregul
product
airway
smooth
muscl
recent
studi
demonstr
rv
induct
increas
smooth
muscl
cell
asthmat
compar
normal
subject
whether
rhinoviru
reach
airway
smooth
muscl
cell
suffi
cient
quantiti
produc
signifi
cant
eff
ect
mechan
vivo
yet
unknown
th
e
eff
ect
respiratori
virus
smooth
muscl
requir
investig
varieti
leukocyt
show
chang
number
site
accumul
activ
state
respons
viru
infect
sinc
cell
also
implic
asthmat
infl
ammat
lower
airway
provid
potenti
site
interact
immunopatholog
viru
infect
asthma
alveolar
macrophag
present
larg
number
lower
airway
th
ey
make
around
cell
seen
bal
normal
volunt
th
ey
ideal
place
earli
phagocytosi
viru
particl
like
play
import
role
immun
respons
antigen
present
tcell
product
cytokin
mediat
rv
shown
enter
human
monocyt
macrophag
express
high
level
major
rv
receptor
possibl
demonstr
rv
replic
within
alveolar
macrophag
although
low
grade
product
infect
shown
monocyt
cell
line
replic
also
occur
macrophag
limit
monocytederiv
macrophag
rel
resist
viral
replic
least
partli
higher
level
type
interferon
product
rv
entri
monocyt
result
activ
product
monocyt
macrophag
rv
induct
b
depend
recent
studi
report
infecti
uvinactiv
rvincreas
releas
macrophag
deriv
resect
lung
tissu
interestingli
infecti
rhinovirusimpair
lp
lipoteicho
acidinduc
secret
macrophag
well
macrophag
phagocyt
respons
label
bacteri
particl
th
rvinduc
impair
cytokin
respons
bacteri
lp
lipoteicho
acid
phagocytosi
alveolar
macrophag
could
lead
impair
antibacteri
host
defens
may
import
implic
pathogenesi
exacerb
respiratori
diseas
includ
asthma
copd
contrast
infect
human
monocyt
vitro
infl
uenza
caus
alter
structur
activ
statu
product
eff
ect
dramat
potenti
subsequ
exposur
bacteri
lp
dendrit
cell
key
cell
ifn
product
well
antigen
present
allergen
pathogen
capac
induc
primari
secondari
immun
respons
th
ey
may
also
play
role
regul
type
tcellmedi
immun
respons
rv
infect
shown
induc
product
dendrit
cell
attract
chemokin
increas
number
lung
rsv
infect
suggest
recruit
lung
respiratori
viru
infect
howev
also
shown
produc
local
precursor
rsv
infect
plasmacytoid
dendrit
cell
like
protect
infect
shown
limit
viru
replic
rsv
infect
well
reduc
airway
infl
ammat
airway
hyperrespons
contrast
other
report
induct
high
affi
niti
ige
receptor
dendrit
cell
sendai
viru
infect
link
induct
mucu
cell
metaplasia
airway
hyperreact
th
ere
thu
increas
knowledg
immunobiolog
cell
respiratori
infect
role
context
viral
exacerb
asthma
remain
unclear
studi
need
bronchial
biopsi
demonstr
increas
cell
posit
within
epithelium
submucosa
normal
asthmat
subject
follow
experiment
rv
infect
recent
demonstr
trend
toward
increas
number
lymphocyt
bal
asthmat
compar
normal
subject
p
increas
coincid
peripher
blood
lymphopenia
reduct
blood
total
lymphocyt
tcell
correl
strongli
viru
load
asthmat
subject
suggest
increas
recruit
tcell
asthmat
airway
may
import
context
asthma
exacerb
sinc
tcell
believ
key
cell
pathogenesi
asthma
eff
ect
virus
tcell
particular
import
tcell
recruit
airway
least
partli
infl
uenc
chemokin
includ
whose
product
ec
upregul
virus
th
e
natur
eff
ectiv
specifi
c
immun
respons
may
infl
uenc
balanc
chemokin
product
airway
ec
th
balanc
may
turn
infl
uenc
preexist
chronic
infl
ammat
found
asthma
studi
clone
tcell
suggest
th
th
cell
show
diff
erenti
express
chemokin
receptor
th
ere
increas
express
receptor
itac
mig
human
th
cell
increas
express
tarc
mdc
lesser
extent
eotaxin
th
cell
select
migrat
cell
respons
appropri
chemokin
rant
found
th
th
cell
bronchial
biopsi
asthmat
show
high
level
express
signific
level
tcell
increas
recruit
tcell
airway
result
virusinduc
chemokin
product
ec
could
amplifi
preexist
allerg
infl
ammat
asthmat
airway
microenviron
infl
uenc
pattern
chemokin
express
follow
viru
infect
could
alter
th
balanc
antivir
immun
respons
th
e
tcell
respons
viru
infect
thought
thelper
th
type
thought
eff
ectiv
antivir
immun
respons
character
product
type
cytokin
addit
monocyt
macrophag
play
role
establish
antivir
state
neighbor
cell
complex
role
pathogenesi
asthma
appear
increas
basophil
mast
cell
histamin
releas
hand
inhibit
express
type
cytokin
product
increas
pbmc
nasal
secret
rv
cold
human
anim
model
infl
uenza
parainfl
uenza
rsv
infect
th
ere
except
antivir
respons
exhibit
th
charact
mixtur
th
anim
model
rsv
diff
erent
protein
viru
may
induc
either
th
th
type
respons
prime
protein
prior
infect
whole
viru
infl
uenc
charact
eff
ectiv
associ
immunopatholog
immun
respons
asthma
believ
character
type
infl
ammat
mani
studi
demonstr
mutual
inhibit
th
th
cell
therefor
possibl
within
airway
preexist
type
allerg
asthmat
microenviron
may
inhibit
normal
eff
ectiv
type
antivir
immun
respons
system
may
skew
toward
type
respons
papadopoulo
et
al
shown
type
respons
rv
defi
cient
individu
asthma
pbmc
taken
asthmat
expos
vitro
rv
show
lower
level
higher
level
cultur
supernat
cell
normal
subject
th
e
ratio
three
time
lower
asthmat
group
studi
gern
et
al
experiment
infect
subject
allerg
rhiniti
asthma
balanc
airway
th
th
cytokin
induc
sputum
induc
viral
infect
found
relat
clinic
symptom
viral
clearanc
although
protein
could
detect
sputum
due
presenc
inhibitor
elisa
assay
use
increas
mrna
determin
semiquantit
rtpcr
invers
correl
demonstr
ratio
mrna
mrna
peak
cold
symptom
addit
subject
still
detect
day
inocul
lower
ratio
acut
phase
cold
subject
clear
viru
recent
investig
product
type
type
cytokin
bal
cell
asthmat
normal
subject
found
product
type
cytokin
suppress
asthmat
product
type
cytokin
increas
importantli
tcell
product
strongli
invers
correl
viru
load
reduct
lung
function
asthmat
subject
underw
rv
experiment
infect
suggest
tcell
product
protect
context
rvinduc
asthma
convers
tcell
product
posit
correl
lower
respiratori
symptom
sever
suggest
tcell
product
associ
sever
exacerb
th
ese
data
novel
import
causal
role
establish
human
challeng
studi
investig
possibl
causal
role
cytokin
vivo
requir
use
newli
develop
mous
model
tcell
import
eff
ector
cell
specifi
c
cellmedi
antivir
immun
th
ey
also
demonstr
polar
cytokin
product
major
cytokin
believ
regul
th
th
balanc
murin
asthma
model
induct
bystand
th
respons
ovalbumin
result
switch
viruspeptid
specifi
c
lung
tcell
product
cytokin
includ
viru
peptid
challeng
induct
airway
eosinophilia
occur
man
suggest
mean
wherebi
antivir
function
could
inhibit
time
amplifi
cation
allerg
infl
ammat
induct
airway
eosinophilia
th
e
role
tcell
product
type
type
cytokin
virusinduc
asthma
exacerb
requir
investig
tcr
tcell
tcr
tcell
minor
subset
tcell
express
receptor
distinct
receptor
found
major
tcell
involv
adapt
immun
th
ere
appear
least
two
type
tcr
tcell
th
e
fi
rst
type
found
lymphoid
tissu
vertebr
display
highli
diversifi
ed
receptor
th
e
second
type
intraepitheli
tcr
tcell
display
receptor
limit
divers
suggest
second
subset
recogn
molecul
express
nearbi
infect
cell
candid
ligand
heatshock
protein
mhc
class
ib
molecul
unorthodox
nucleotid
phospholipid
antigen
recogn
directli
rather
process
peptid
present
mhc
recognit
molecul
express
consequ
infect
rather
pathogenspecifi
c
molecul
would
place
tcr
tcell
intersect
innat
adapt
immun
howev
exagger
respons
variou
pathogen
self
tissu
found
studi
mice
defi
cient
tcr
tcell
rather
defi
cienci
control
pathogen
work
suggest
least
tcr
tcell
regulatori
role
modul
immun
respons
function
consist
demonstr
abil
secret
regulatori
cytokin
activ
report
tcr
tcell
numer
asthmat
airway
recent
studi
found
greater
capac
product
bronchoalveolar
lavag
tcr
tcell
asthmat
subject
viru
infect
result
releas
molecul
epitheli
cell
activ
tcr
tcell
respiratori
mucosa
cell
could
provid
sourc
type
cytokin
infl
uenc
natur
subsequ
immun
respons
th
e
role
tcr
tcell
virusinduc
asthma
exacerb
requir
investig
eosinophil
increas
bronchial
epithelium
biopsi
taken
normal
asthmat
volunt
follow
experiment
rv
infect
small
studi
eosinophil
infl
ammat
persist
week
asthmat
subject
recent
studi
eosinophil
number
bal
signifi
cantli
threefold
increas
asthmat
compar
normal
subject
acut
rv
infect
correl
signifi
cantli
reduct
lung
function
asthmat
subject
allerg
rhiniti
experiment
rv
infect
increas
bal
eosinophil
follow
segment
allergen
challeng
persist
week
increas
level
ecp
found
sputum
rvinfect
subject
natur
occur
acut
exacerb
asthma
eosinophil
accumul
airway
infl
uenc
gmcsf
rant
eotaxin
shown
produc
airway
ec
vitro
infect
rv
express
rant
increas
nasal
secret
children
natur
virusinduc
asthma
rant
upregul
primari
nasal
ec
cultur
rsv
rv
gmcsf
import
bone
marrow
eosinophil
product
eosinophil
surviv
level
increas
viral
upper
respiratori
tract
infect
level
eotaxin
nasal
lavag
rise
experiment
infect
th
ese
data
suggest
pathogen
role
eosinophil
virusinduc
asthma
howev
protect
role
also
possibl
allerg
rhinit
subject
infect
rv
high
dose
allergen
challeng
sever
durat
cold
symptom
invers
relat
nl
eosinophil
count
prior
infect
eosinophil
may
contribut
viral
antigen
present
eosinophil
pretreat
gmcsf
bind
via
present
viral
antigen
c
tcell
induc
prolifer
secret
eosinophil
antivir
action
parainfl
uenzainfect
guinea
pig
edn
ecp
ribonucleas
activ
reduc
rsv
infect
th
e
role
eosinophil
antivir
immun
respons
thu
requir
evalu
th
ese
cell
import
sourc
infl
ammatori
mediat
characterist
allerg
infl
ammat
asthma
mast
cell
basal
stimul
histamin
releas
increas
viru
infect
airway
mast
cell
number
upregul
rat
model
parainfl
uenza
infect
sever
virus
enhanc
basophil
igemedi
histamin
releas
role
cell
human
asthma
controversi
mast
cell
also
import
sourc
infl
ammatori
mediat
th
eir
function
local
suggest
earli
interact
virus
leukotrien
lt
c
among
mediat
respons
late
phase
bronchospasm
asthma
rsv
infect
increas
level
ltc
found
nasopharyng
secret
infant
level
correl
well
symptom
diseas
concentr
infant
present
bronchiol
fi
vefold
higher
upper
respiratori
tract
symptomatolog
cultur
alveolar
macrophag
infect
parainfl
uenza
viru
respond
increas
arachidon
acid
metabol
sever
product
pathway
known
induc
airway
constrict
includ
ltc
ltd
pgf
thromboxan
andor
stimul
mucou
secret
pgf
ltb
acid
rv
infect
shown
induc
prostaglandin
lt
synthet
enzym
bronchial
biopsi
normal
subject
well
trend
increas
number
mast
cell
p
bronchoalveolar
lavag
fl
uid
cysteinylleukotrien
level
p
outcom
studi
asthmat
subject
neutrophil
recruit
earli
respiratori
viral
infect
respons
product
ec
activ
neutrophil
promin
featur
sever
asthma
induc
sputum
asthmat
nonasthmat
demonstr
signifi
cant
increas
neutrophil
day
natur
cold
correl
sputum
similar
result
obtain
taken
day
experiment
infect
asthmat
intracellular
stain
demonstr
increas
cell
posit
day
attribut
increas
posit
neutrophil
th
e
chemokin
potent
chemoattract
neutrophil
also
act
lymphocyt
basophil
prime
eosinophil
increas
found
nl
children
natur
cold
experiment
infect
asthmat
result
elev
nl
correl
coldasthma
symptom
score
histamin
asthmat
exacerb
elev
neutrophilia
studi
experiment
infect
asthmat
children
also
demonstr
elev
neutrophilia
nl
acut
infect
level
neutrophil
myeloperoxidas
correl
symptom
sever
asthma
exacerb
asthmat
adult
viru
infect
increas
sputum
neutrophil
increas
neutrophil
elastas
sever
clinic
diseas
studi
suggest
promin
role
neutrophil
tissu
damag
virusinduc
asthma
natur
killer
nk
cell
import
part
innat
immun
respons
function
elimin
varieti
target
cell
includ
virusinfect
cell
modul
adapt
immun
toward
virus
cell
kill
nk
cell
may
occur
natur
kill
antibodydepend
cellular
cytotox
adcc
apoptot
kill
fasposit
target
cell
via
membran
bound
fasl
th
e
abil
directli
kill
virusinfect
cell
regul
balanc
inhibitori
activ
receptor
killer
inhibitori
receptor
kir
iglik
receptor
recogn
hlaa
b
c
molecul
lectinlik
receptor
interact
hlae
allow
nk
cell
recogn
cell
express
normal
self
mhc
class
loss
inhibit
occur
potenti
target
cell
lost
class
express
follow
viru
infect
display
abnorm
class
ipeptid
complex
nk
cell
rapid
effi
cient
produc
cytokin
import
earli
viral
infect
antigenindepend
activ
antigen
present
cell
macrophag
dendrit
cell
epitheli
cell
bias
develop
th
cell
cytokin
chemokin
shown
enhanc
activ
nk
cell
vitro
vivo
includ
rant
transform
growth
factor
tgf
inhibit
nk
cell
activ
type
cytokin
may
also
modul
nk
function
increas
nk
type
activ
decreas
nk
type
activ
human
nk
cell
cultur
medium
supplement
diff
erenti
nk
type
cell
secret
cultur
presenc
diff
erenti
nk
type
cell
secret
also
shown
suppress
cytolyt
prolif
activ
product
human
nk
cell
nk
cell
product
enhanc
reduc
mous
model
asthma
intracellular
stain
nk
cell
demonstr
product
deplet
nk
cell
result
reduc
airway
eosinophilia
th
e
function
nk
cell
asthmat
airway
yet
unexplor
may
airway
environ
rich
type
cytokin
nk
type
function
eff
ectiv
antivir
activ
inhibit
case
key
compon
earli
immun
respons
would
defi
cient
viral
clearanc
would
impair
addit
nk
type
function
favor
asthmat
microenviron
product
type
cytokin
nk
cell
respons
viru
infect
might
one
mechan
amplifi
cation
allerg
infl
ammat
th
ese
hypothes
yet
untest
human
studi
experiment
viru
infect
elev
serum
total
allergenspecifi
c
ige
featur
extrins
atop
asthma
igemedi
mechan
certainli
import
pathophysiolog
extrins
asthma
recent
studi
suggest
similar
airway
patholog
extrins
intrins
nonatop
asthma
absenc
specifi
c
serum
ige
neg
skin
prick
test
aeroallergen
suggest
may
product
local
ige
yet
unknown
environment
allergen
intrins
asthma
upregul
total
ige
virusallergenspecifi
c
ige
local
system
respiratori
viru
infect
would
expect
contribut
durat
sever
symptom
asthma
exacerb
intranas
challeng
result
increas
total
serum
ige
allerg
rhinit
subject
increas
preexist
allergenspecifi
c
ige
children
asthma
infect
infl
uenza
chang
total
ige
increas
observ
specifi
c
serum
ige
hous
dust
mite
ex
vivo
prolif
respons
lymphocyt
challeng
hous
dust
mite
allergen
studi
rsv
infect
infant
develop
serum
rsvspecifi
c
ige
occur
frequent
atop
correl
clinic
wheez
histamin
level
nasal
secret
hypoxia
th
ere
inform
yet
presenc
local
virusspecifi
c
ige
airway
asthma
exacerb
increas
interest
clinic
featur
pathogenesi
copd
refl
ect
worldwid
import
diseas
million
patient
aff
ect
unit
state
alon
predict
becom
third
lead
caus
death
worldwid
nation
global
initi
launch
manag
guidelin
publish
th
e
frequenc
exacerb
major
factor
qualiti
life
patient
copd
th
e
typic
clinic
featur
exacerb
includ
increas
dyspnea
wheez
cough
sputum
product
worsen
ga
exchang
although
noninfecti
caus
exacerb
allergi
air
pollut
inhal
irrit
includ
cigarett
smoke
may
import
acut
airway
infect
major
precipit
th
e
infect
consequ
host
infl
ammatori
respons
result
increas
airway
obstruct
like
twothird
threequart
copd
exacerb
may
caus
viral
infect
studi
patient
rhinovirus
infl
uenza
viru
parainfl
uenza
viru
coronaviru
signifi
cantli
associ
copd
exacerb
exacerb
associ
preced
symptom
common
cold
th
e
frequenc
exacerb
requir
hospit
higher
winter
one
explan
could
increas
frequenc
respiratori
virus
time
year
recent
studi
exacerb
patient
moder
sever
copd
use
new
diagnost
method
includ
rtpcr
show
high
incid
viral
infect
virus
detect
nasal
aspir
exacerb
almost
case
rhinoviru
common
occur
case
viru
present
th
e
presenc
viru
associ
increas
dyspnea
cold
symptom
sore
throat
prolong
recoveri
exacerb
earlier
studi
reli
serolog
viru
cultur
quot
lower
viru
detect
rate
studi
sever
exacerb
use
comprehens
pcr
method
confi
rmed
import
viru
infect
virus
detect
around
exacerb
studi
involv
sampl
rel
late
cours
ill
like
detect
rate
underestim
true
import
viru
infect
th
e
role
bacteria
precipit
exacerb
also
somewhat
controversi
bacteria
may
primari
role
develop
exacerb
andor
repres
secondari
superinfect
initi
viral
process
variou
bacteri
speci
present
airway
patient
even
copd
stabl
increas
frequenc
recoveri
bacteria
exacerb
well
higher
bacteri
load
exacerb
suggest
play
import
role
signifi
cant
number
signifi
cant
bacteri
infect
suggest
abund
neutrophil
sputum
sputum
purul
green
due
neutrophil
myeloperoxidas
bacteria
may
contribut
pathogenesi
exacerb
due
increas
bacteri
load
bacteria
alreadi
colon
diseas
airway
howev
addit
acquisit
new
bacteri
strain
also
shown
import
increas
risk
exacerb
twofold
th
e
major
bacteri
organ
associ
copd
exacerb
nontyp
haemophili
infl
uenza
streptococcu
pneumonia
moraxella
branhamella
catarrhali
mycoplasma
pneumonia
chlamydia
pneumonia
may
play
part
evid
also
suggest
sever
patient
baselin
fev
predict
less
gramneg
bacteria
especi
enterobacteriacea
pseudomona
play
import
part
acut
exacerb
recent
studi
address
role
coinfect
bacteria
virus
one
studi
show
occur
exacerb
patient
dual
infect
mark
lung
function
impair
longer
hospit
anoth
report
exacerb
cold
symptom
marker
put
viral
infect
bacteri
pathogen
fev
fall
greater
symptom
count
higher
bacteri
pathogen
alon
th
us
even
exacerb
virus
detect
bacteria
also
contribut
exacerb
sever
although
result
placebocontrol
trial
show
confl
ict
result
overal
eff
ect
antibiot
treatment
also
support
etiolog
role
bacteria
exacerb
patient
metaanalysi
nine
studi
show
small
overal
benefi
antibiot
use
copd
exacerb
th
e
largest
studi
includ
exacerb
outpati
compar
placebo
rate
symptom
resolut
improv
peak
expiratori
fl
ow
exacerb
slightli
significantli
faster
patient
treat
cotrimoxazol
amoxicillin
doxycyclin
importantli
treatment
failur
defi
ned
respiratori
deterior
nearli
twice
like
placebo
group
benefi
antibiot
evid
patient
symptom
dyspnea
increas
sputum
volum
sputum
purul
guidelin
use
antibiot
acut
exacerb
copd
unclear
diffi
culti
defi
ning
role
bacteri
infect
individu
case
th
e
american
th
orac
societi
statement
copd
suggest
use
antibiot
evid
infect
fever
leukocytosi
cxr
chang
patient
bacteri
bronchial
infect
fever
common
viral
infect
pneumonia
cxr
chang
th
e
european
respiratori
societi
recommend
antibiot
sputum
purul
use
standard
antibiot
fi
rst
line
sputum
cultur
fail
bacteri
infect
defi
nite
role
pathogenesi
chronic
lung
diseas
cystic
fi
brosi
bronchiectasi
bacteri
infect
chronic
caus
acut
exacerb
also
infl
uenc
longterm
prognosi
diseas
chronic
bacteri
infect
occur
host
immun
respons
unabl
clear
bacteria
continu
infect
lead
continu
infl
ammatori
respons
continu
tissu
damag
host
bacteri
factor
attract
activ
neutrophil
produc
proteinas
reactiv
oxygen
speci
lung
antiproteinas
defens
overwhelm
proteinas
enzym
reactiv
oxygen
speci
caus
damag
epithelium
stimul
mucu
product
impair
mucociliari
clearanc
neutrophil
elastas
stimul
epitheli
cell
product
chemokin
attract
neutrophil
addit
impair
phagocytosi
destroy
antibodi
cleav
complement
receptor
neutrophil
complement
compon
bacteria
neutrophil
also
stimul
cigarett
smoke
identifi
cation
bacteria
exacerb
also
associ
increas
level
infl
ammatori
mediat
bal
andor
sputum
th
ese
includ
reactiv
oxid
speci
neutrophil
elastas
ltb
myeloperoxidas
mani
other
th
ese
clearli
potenti
caus
consider
tissu
damag
well
recruit
activ
infl
ammatori
cell
copd
patient
particularli
sever
end
diseas
spectrum
may
also
chronic
colon
bacteria
exacerb
bacteri
number
increas
exacerb
studi
use
bronchoscop
protect
brush
specimen
copd
patient
colon
bacteria
stabl
exacerb
bacteria
present
present
bacteri
number
greater
protect
brush
specimen
taken
sever
acut
exacerb
copd
requir
ventil
bacteria
detect
possibl
distinguish
patient
like
bacteria
basi
clinic
featur
investig
th
e
major
bacteri
pathogen
isol
bronchial
infect
form
part
commens
fl
ora
nasopharynx
bronchial
infect
occur
patient
abnorm
airway
reduc
host
defens
persist
bacteria
within
bronchial
tree
may
come
toxin
impair
mucociliari
clearanc
enzym
breakdown
local
immunoglobulin
product
alter
immun
eff
ector
cell
function
adher
mucu
damag
epithelium
mechan
avoid
immun
surveil
bacteri
colon
stabl
state
repres
equilibrium
number
bacteria
present
bronchial
tree
contain
host
defens
elimin
exacerb
equilibrium
upset
bacteri
number
increas
incit
infl
ammatori
respons
chang
usual
occur
chang
host
rather
alter
virul
bacteria
exampl
result
viral
infect
exacerb
associ
viral
infect
also
increas
level
mani
infl
ammatori
mediat
also
found
bacteri
exacerb
includ
neutrophil
elastas
myeloperoxidas
ltb
contrast
bacteri
exacerb
neutrophil
neutrophil
product
predomin
viral
exacerb
neutrophil
eosinophil
present
eosinophil
product
ecp
also
increas
mediat
implic
includ
rant
also
suggest
persist
viru
infect
contribut
progress
copd
particular
adenoviru
appear
persist
latent
form
viral
protein
produc
without
replic
complet
viru
latent
infect
may
amplifi
lung
infl
ammat
due
cigarett
smoke
adenovir
dna
persist
human
lung
patient
copd
compar
patient
similar
age
sex
smoke
histori
copd
th
e
protein
demonstr
airway
epitheli
cell
smoker
abl
amplifi
mani
host
gene
attach
dnabind
site
transcript
factor
airway
epitheli
cell
transfect
produc
excess
infl
ammatori
cytokin
surfac
adhes
molecul
vitro
challeng
bdepend
mechan
rsv
identifi
ed
induc
sputum
patient
stabl
copd
th
ese
individu
higher
plasma
fi
brinogen
serum
higher
pco
increas
frequenc
exacerb
th
suggest
either
low
grade
persist
rsv
infect
contribut
copd
sever
patient
sever
copd
less
abl
clear
rsv
airway
th
e
immunolog
viru
infect
copd
well
understood
less
data
avail
viru
infect
asthma
sinc
major
subject
human
experiment
infect
studi
small
safeti
studi
four
patient
inocul
low
dose
result
symptomat
cold
viral
replic
signifi
cant
increas
lower
respiratori
tract
symptom
reduct
pef
fev
typic
acut
exacerb
copd
studi
clearli
need
view
increas
evid
major
role
virus
caus
copd
exacerb
current
much
treatment
infect
exacerb
asthma
copd
symptomat
consist
increas
bronchodil
either
shortact
agonist
inhal
intraven
form
anticholinerg
theophyllin
support
form
oxygen
sever
case
noninvas
invas
ventilatori
measur
corticosteroid
wide
use
inhal
oral
form
antiinfl
ammatori
action
th
e
eff
ect
corticosteroid
result
action
mani
point
variou
infl
ammatori
cascad
whilst
undoubtedli
contribut
benefi
cial
eff
ect
also
result
signifi
cant
local
system
side
eff
ect
particular
oral
steroid
treatment
prolong
frequent
addit
system
steroid
may
interfer
antivir
immun
respons
result
reduc
viral
clearanc
persist
asthma
control
diseas
achiev
predominantli
inhal
corticosteroid
th
ere
role
addit
drug
longact
agonist
leukotrien
antagonist
th
e
longact
agonist
particular
appear
increas
eff
ectiv
inhal
corticosteroid
allow
dose
need
achiev
control
reduc
th
ere
also
evid
drug
combin
inhal
corticosteroid
may
reduc
exacerb
frequenc
th
e
leukotrien
antagonist
appear
eff
ectiv
treat
prevent
exacerb
children
regular
corticosteroid
treatment
howev
partial
eff
ectiv
prevent
exacerb
adult
asthma
inhal
steroid
reduc
exacerb
frequenc
school
age
children
inhal
steroid
ineff
ectiv
reduc
exacerb
frequenc
durat
sever
preschool
age
children
virusinduc
wheez
oral
steroid
ineff
ectiv
even
prime
eosinophil
specifi
c
antibiot
therapi
avail
bacteri
infect
indic
good
evid
infect
exacerb
sever
bacteri
involv
possibl
howev
discuss
major
infect
asthma
exacerb
viral
rather
bacteri
origin
virus
also
common
exacerb
copd
th
e
success
vaccin
prevent
respiratori
viru
infect
limit
signifi
cant
variat
within
major
viru
type
caus
diseas
th
ere
serotyp
strain
rhinoviru
sever
serotyp
eff
ectiv
vaccin
introduc
decaval
vaccin
develop
ultim
limit
effi
caci
th
e
infl
uenza
virus
display
antigen
shift
drift
vaccin
must
modifi
ed
everi
year
cover
strain
preval
time
vaccin
rsv
experienc
major
setback
use
formalininactiv
viru
young
babi
result
increas
diseas
sever
follow
subsequ
viru
infect
eighti
percent
vaccin
children
requir
hospit
subsequ
infect
rsv
compar
control
th
e
lung
two
vaccin
children
die
contain
eosinophil
infi
ltrate
suggest
formalin
inactiv
may
modifi
ed
epitop
within
rsv
g
f
surfac
glycoprotein
result
modifi
ed
immun
respons
subsequ
infect
enhanc
immunopatholog
vaccin
individu
demonstr
number
diff
erenc
individu
suff
ere
natur
rsv
infect
includ
lack
specifi
c
mucos
antibodi
defi
cient
neutral
fusioninhibit
serum
antibodi
th
ere
also
diff
erenc
cellmedi
immun
respons
vaccin
individu
demonstr
peripher
eosinophilia
exagger
lymphocyt
prolif
respons
rsv
protect
rsv
infect
success
vaccin
would
need
provid
eff
ectiv
protect
natur
infect
frequent
follow
reinfect
would
administ
earli
infanc
eff
ect
infant
bronchiol
simpl
nonspecifi
c
treatment
common
cold
exist
although
effi
caci
debat
vitamin
c
zinc
glucon
may
shorten
durat
cold
day
th
e
inhal
humidifi
ed
hot
air
provid
symptomat
relief
nasal
eff
ectiv
treatment
common
cold
must
given
either
prior
shortli
exposur
viru
also
expens
associ
signifi
cant
local
side
eff
ect
bleed
discharg
th
ese
problem
limit
clinic
use
howev
ifn
therapi
virusinduc
asthma
exacerb
may
use
view
defi
cienci
identifi
ed
recent
studi
larg
number
virus
produc
similar
clinic
syndrom
gener
antivir
properti
ifn
would
provid
signifi
cant
advantag
use
specifi
c
antivir
drug
specifi
c
antivir
agent
exist
infl
uenza
amantidin
rimantidin
eff
ectiv
infl
uenza
th
e
use
amantidin
limit
cn
side
eff
ect
dizzi
insomnia
fewer
side
eff
ect
seen
rimantidin
drug
indic
epidem
treatment
prophylaxi
high
risk
group
includ
asthmat
neither
activ
infl
uenza
b
two
neuraminidas
inhibitor
zanamivir
oseltamivir
activ
infl
uenza
b
th
ese
agent
eff
ectiv
prevent
infect
use
prophylaxi
infl
uenza
season
treatment
reduc
durat
ill
start
within
h
onset
ill
zanamivir
must
given
inhal
wherea
oseltamivir
given
oral
ribavirin
nucleosid
analog
activ
rsv
vivo
also
infl
uenza
vitro
nebul
ribavirin
therapi
licens
use
hospit
infant
children
fi
rst
day
rsv
bronchiol
howev
expens
unproven
benefi
clinic
outcom
toxic
appropri
asthma
rsv
enrich
immunoglobulin
eff
ectiv
prophylaxi
infant
high
risk
rsv
bronchiol
supersed
rsv
neutral
monoclon
antibodi
rv
major
target
drug
treatment
estim
rhinovirus
result
cold
per
year
young
children
yet
eff
ectiv
agent
avail
clinic
use
capsidbindingcanyon
inhibitor
block
rv
bind
host
cell
receptor
case
major
group
one
exampl
phase
clinic
trial
pleconaril
picovir
th
ese
drug
extrem
potent
clinic
use
often
limit
toxic
need
rapid
initi
therapi
possibl
develop
resist
altern
target
includ
solubl
inhibit
major
rhinoviru
infect
conserv
viral
enzym
protein
rnadepend
rna
transcriptas
protein
associ
atphelicas
cystein
proteas
altern
approach
direct
antivir
therapi
suppress
virusinduc
infl
ammat
strategi
promot
innat
type
immun
respons
individu
excess
type
respons
understand
complex
antivir
immun
respons
particular
may
alter
context
preexist
chronic
airway
diseas
asthma
essenti
fi
rst
step
work
need
elucid
import
site
interact
immunolog
network
asthma
viru
infect
greater
knowledg
requir
identifi
key
target
therapeut
intervent
aim
minim
immunopatholog
whilst
maintain
enhanc
host
antivir
immun
respons
